NEW YORK (Thomson Financial) - Seattle Genetics Inc. Friday said a 10
million share public offering had been priced at $9 a share.
The Bothell, Wash.-based pharmaceutical company listed JPMorgan and UBS as
book-running managers in the offering, and granted underwriters an option to buy
up to an additional 1.5 million shares.
The company expects $84.4 million in proceeds from the offering, which it
said it plans to use to fund research and development, and for general corporate
purposes.
The offering is expected to close on Jan. 24.
Ryan Vlastelica
rv/pc
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|